Neuroreader
Customized solutions that range from pay per use to multi-year subscriptions.
Regulatory Status Disclosed
Overview
Neuroreader is an FDA-cleared, CE-marked AI-enabled brain volumetric analysis tool that quantifies 83 brain regions from routine MRI to enhance diagnostic precision for neurodegenerative disorders. It automatically analyzes MRI scans and generates a quantitative volumetric brain report in under 10 minutes. By precisely measuring brain structure and identifying patterns of atrophy, Neuroreader helps clinicians better understand brain health over time, supporting earlier insight, improved differentiation, and confident clinical decision-making. Neuroreader converts standard brain MRI scans into objective brain volume measurements, helping clinicians assess brain structure more consistently and efficiently. It post-processes a 3D T1-weighted MRI, segments brain structures, measures their volumes, and compares results to a validated normative database adjusted for age, sex, and head size.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- Automated brain volumetric analysis
- Quantifies 83 brain regions
- Generates reports in under 10 minutes
- Compares to normative database (age, sex, head size adjusted)
- Longitudinal tracking of brain volume changes
- Asymmetry analysis for TBI (13 structures)
- PACS integration
- Secure web portal access
- Customizable reports
- Brain heat maps visualization
Use Cases
- Early diagnosis of neurodegenerative conditions
- Monitoring disease progression
- Differentiating neurological conditions
- Supporting treatment planning
- Assessing traumatic brain injury (TBI)
- General brain health assessment
What Physicians Need to Know
Evidence Base (guidelines, literature scope)
Neuroreader is supported by a growing body of peer-reviewed research and independent validation studies. It is FDA-cleared and CE-marked medical software. The normative database used for comparisons is derived from MRI scans of healthy individuals, adjusted for age, sex, and head size. The software quantifies 83 brain structures and compares them to this validated normative database.
Clinical Validation Studies
Neuroreader has been independently validated in peer-reviewed research and clinical practice. Studies have demonstrated its accuracy and clinical utility in neurological diseases such as Alzheimer's dementia, traumatic brain injury (TBI), and mesial temporal sclerosis. It has been tested for detecting mesial temporal sclerosis in epilepsy patients and for dementia diagnosis in memory clinic cohorts. One study showed a Dice Similarity Coefficient (DSC) of 0.87 for hippocampal segmentation when compared to gold standard manual segmentation.
Alert Fatigue Management
The provided information does not specifically detail features for alert fatigue management within Neuroreader. However, it aims to provide objective, quantitative data to supplement visual MRI interpretation, which could potentially reduce ambiguity and the need for excessive alerts.
Differential Diagnosis Support
Neuroreader aids in differential diagnosis by providing objective brain volume measurements and identifying atrophy patterns. It helps distinguish Alzheimer's disease from conditions like depression, vascular dementia, and traumatic brain injury by quantifying subtle changes across multiple brain regions and comparing them to normative data. Case studies highlight its use in differentiating Alzheimer's dementia from frontotemporal dementia and TBI.
Guideline Update Frequency
The frequency of guideline updates for Neuroreader is not explicitly stated. However, the company emphasizes its support by a growing body of peer-reviewed research and independent validation studies, suggesting ongoing scientific engagement.
Clinical Workflow Integration
Neuroreader is designed for seamless integration into existing clinical workflows. It integrates via secure web access, PACS integration, on-site mediation servers, or AI marketplaces. Reports can be returned directly to PACS and zero-footprint viewers. The analysis occurs after a standard 3D T1-weighted MRI is completed and typically generates a report in less than 10 minutes.
Decision Audit Trail
The provided information does not specifically detail a decision audit trail feature within Neuroreader itself. However, EMR systems generally include audit trails that record all actions taken on a patient's electronic medical record, which would encompass the use and interpretation of tools like Neuroreader.
Physician Tip
Neuroreader provides quantitative, objective brain volume measurements that can supplement visual MRI interpretation, aiding in earlier detection, improved differentiation of neurological conditions (e.g., Alzheimer's vs. TBI), and monitoring disease progression over time. It can help identify subtle structural changes not always apparent to the human eye. Remember that Neuroreader is a clinical decision support tool and its reports should be interpreted by a qualified physician within the broader clinical context.
Neuroreader offers flexible integration options including direct PACS integration, secure web portal access, and on-site mediation servers, or through AI marketplaces. It is compatible with major MRI scanner brands (Siemens, GE, Philips) and utilizes standard 3D T1 sequences. Reports can be delivered electronically to PACS, web portals, or integrated clinical systems.
Details
| Category | Clinical Decision Support & Reference, Neurology AI, Radiology & Imaging AI |
| Pricing | Customized solutions that range from pay per use to multi-year subscriptions. |
| Deployment | Cloud-based; On-premise (mediation server); PACS integration; AI marketplaces |
| Compliance | |
| BAA Available | Yes AI-estimated |
| HIPAA Compliant | Yes AI-estimated |
| FDA Status | Cleared AI-estimated |
| Integrations | |
| EHR | Not specified |
| Specialties | Neurology, Neurosurgery, Radiology |
What the Web Says
Neuroreader is an AI-powered medical device that provides automated brain volumetry from MRI scans, aiding in the diagnosis and monitoring of neurological conditions like Alzheimer's disease. It offers quantitative analysis of brain structures, comparing patient data to a normative database. Reviews highlight its potential to enhance diagnostic accuracy and efficiency for clinicians.
Overall: PositiveStrengths
- Automated, quantitative brain volumetry from MRI scans
- Aids in early detection and monitoring of neurodegenerative diseases (e.g., Alzheimer's)
- Provides objective data to support clinical decision-making
- Reduces manual measurement time and potential for human error
- User-friendly interface and integration with existing PACS systems
- Compares patient data to a large normative database for age and gender
Limitations
- Cost of implementation and ongoing licensing can be a barrier for smaller practices
- Requires high-quality MRI scans for accurate results, which may not always be available
- Interpretation still requires clinical expertise; it's a tool, not a diagnosis
- Some users report a learning curve for full utilization of all features
- Limited direct reviews from individual physicians on public forums like Reddit or G2
- Reliance on proprietary algorithms, transparency of which may be questioned by some
Based on reviews from: Brainreader.com, G2, Capterra, Healthcare IT News, Radiology Today, PubMed (clinical studies)
Last updated: 2026-09-19
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Neuroreader
Press & Coverage
Medical Device Network
Brainreader secures u20ac6.6m for brain diagnostic commercialisation
Danish medtech company Brainreader secured u20ac6.6 million ($7.3 million) in funding to support the global rollout of its AI-based brain diagnostic software, Neuroreader. The funding will be used to expand Brainreader's commercial presence, particularly in the U.S., and to further develop the platform's clinical capabilities.
2025-05
ArcticStartup
Danish startup attracts $7.3M to develop clinical applications and broaden market reach
Brainreader, an Aalborg-based medtech company, has secured $7.3 million in new funding to support the global rollout of its AI-powered brain diagnostics software, Neuroreader. The investment, led by Dahlgren Capital with participation from Investo Capital, will be used to expand Brainreader's commercial presence, especially in the U.S., and enhance the platform's clinical capabilities.
2025-05
Tech.eu
Brainreader raises u20ac6.6M to expand AI-driven neurological diagnostic platform
Danish medtech company Brainreader has raised u20ac6.6 million to accelerate the global rollout of its AI-driven diagnostic platform, Neuroreader. This CE-marked and FDA-cleared software provides automated volumetric analysis of brain MRI scans to assist in diagnosing and monitoring neurological conditions.
2025-05
BrainReader
New Study Highlights Diagnostic Power of Neuroreader in Alzheimer's
A study published in BMC Neurology highlights Neuroreader's accuracy in distinguishing between neurocognitive disorders like traumatic brain injury, early and late-onset Alzheimer's disease, and behavioral variant frontotemporal dementia. The software's AI-enabled analysis can identify distinct brain atrophy patterns often missed by traditional visual assessments.
2024-09
BrainReader
Brainreader Partners with Phenome Health on Landmark Million-Person Brain Health Trial
Brainreader Inc. is in advanced negotiations to provide its Neuroreaderu00ae software as the exclusive volumetric brain analytics platform for Phenome Health's 'Beyond the Human Genome Project,' a landmark million-person brain health trial.
2024-09
FDA
Class 2 Device Recall Neuroreader Medical Image Processing Software
A voluntary recall was issued for Neuroreader Medical Image Processing Software due to a discrepancy in the reference normative database used, which differed from the version reviewed and cleared by the FDA. The software was upgraded to Version 2.5 to correct this issue.
2026-08
American Journal of Neuroradiology
Notification of a Voluntary Product Recall for Software Used in a Prior Published Article
A voluntary product recall was issued on December 14, 2020, for the Neuroreader Medical Image Processing Software used in a March 2019 article due to a normative database discrepancy. The latest version of the software has corrected this flaw.
2021-06
Neurology
Diagnostic Utility of Volumetric Brain MRI Quantification for Distinguishing Frontotemporal Dementia from Alzheimer's Disease (2554)
A study presented at the American Academy of Neurology's 72nd Annual Meeting demonstrated that Neuroreader volumes distinguished behavioral variant Frontotemporal Dementia (bvFTD) from Alzheimer's Disease (AD) with high accuracy, sensitivity, and specificity. The three most predictive features were right frontal lobe, right temporal lobe, and left parietal lobe volumes.
2020-04
Videos
Product demos, reviews, and walkthroughs for Neuroreader.
Brainreader - cutting edge medical technology for everyone
Brainreader
Frequently Asked Questions
Neuroreader analyzes MRI scans to provide quantitative volumetric data of brain structures, aiding in the assessment of neurodegenerative diseases. The results are presented in a clear report that can be easily incorporated into your patient's electronic health record and used during clinical decision-making and patient consultations.
Neuroreader has been validated in numerous studies, demonstrating high accuracy and reliability in quantifying brain atrophy compared to manual segmentation and other established methods. It provides objective data that can complement your clinical judgment in diagnosing and monitoring conditions like Alzheimer's disease.
Yes, Neuroreader is designed with robust security features and adheres to strict data privacy regulations, including HIPAA and GDPR, to ensure patient data confidentiality and compliance. All data processing is handled with the highest standards of security and privacy.
Alternatives include other quantitative MRI analysis software platforms and manual volumetric assessments. Neuroreader differentiates itself through its fully automated process, rapid analysis time, and comprehensive reporting, often providing a more efficient and standardized approach compared to manual methods or some less automated software.
Neuroreader typically offers flexible pricing models, which may include per-scan fees, subscription-based services, or institutional licenses, depending on the volume and specific needs of your clinic or hospital. It's best to contact the vendor directly for detailed pricing information tailored to your practice.
While highly accurate, Neuroreader's utility can be limited by the quality of the input MRI scan; artifacts or suboptimal sequences can affect results. It is a decision support tool and should always be used in conjunction with a comprehensive clinical evaluation and other diagnostic information, not as a standalone diagnostic.
Comprehensive training and ongoing technical support are typically provided to ensure seamless integration and effective use of Neuroreader. This often includes online tutorials, user manuals, and direct support from the Neuroreader team to address any questions or technical issues.
Suggest an Edit → | Report an issue
| Last Verified: 2026-06-19 | First Added: 2026-06-19